Abstract
Introduction: In critically ill patients requiring intermittent renal replacement therapy (RRT), the benefits of convective versus diffusive clearance remain uncertain. We conducted a systematic review and meta-analysis to determine the safety, clinical efficacy, and clearance efficiency of hemofiltration (HF) and hemodiafiltration (HDF) compared to hemodialysis (HD) in patients with acute kidney injury (AKI) receiving intermittent RRT. Method: We searched Medline, Embase, Cochrane Library, and PROSPERO. We included clinical trials and observational studies that reported the use of intermittent HF or HDF in adult patients with AKI. The following outcomes were included: mortality, renal recovery, clearance efficacy, intradialytic hemodynamic stability, circuit loss, and inflammation modulation. Results: A total of 3,169 studies were retrieved and screened. Four randomized controlled trials and 4 observational studies were included (n: 615 patients). Compared with conventional HD, intermittent convective therapies had no effect on in-hospital mortality (relative risk, 1.23; 95% confidence interval (CI), 0.76–1.99), renal recovery at 30 days (RR, 0.98; 95% CI, 0.82–1.16), time-to-renal recovery (mean difference [MD], 0.77; 95% CI, −6.56 to 8.10), and number of dialysis sessions until renal recovery (MD, −1.34; 95% CI, −3.39 to 0.72). The overall quality of included studies was low, and dialysis parameters were suboptimal for all included studies. Conclusion: This meta-analysis suggests that there is no significant difference in short-term mortality and renal recovery in patients with severe AKI when treated with intermittent HF or HDF compared to conventional HD. This systematic review emphasizes the need for further trials evaluating optimal convective parameters in AKI patients treated with intermittent dialysis.
References
1.
Klouche
K
, Amigues
L
, Morena
M
, Brunot
V
, Dupuy
AM
, Jaussent
A
, On-line hemodiafiltration did not induce an overproduction of oxidative stress and inflammatory cytokines in intensive care unit-acute kidney injury
. BMC Nephrol
. 2017
;18
(1
):371
. .2.
Filiponi
TC
, de Souza Durão
M
Jr. How to choose the ideal renal replacement therapy in sepsis?
Shock
. 2013
;39
(Suppl 1
):50
–3
. .3.
Nash
DM
, Przech
S
, Wald
R
, O’Reilly
D
. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit
. J Crit Care
. 2017
;41
:138
–44
. .4.
Uchino
S
, Kellum
JA
, Bellomo
R
, Doig
GS
, Morimatsu
H
, Morgera
S
, Acute renal failure in critically ill patients: a multinational, multicenter study
. JAMA
. 2005
;294
(7
):813
–8
. .5.
Schneider
AG
, Bellomo
R
, Bagshaw
SM
, Glassford
NJ
, Lo
S
, Jun
M
, Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis
. Intensive Care Med
. 2013
;39
(6
):987
–97
. .6.
Rabindranath
K
, Adams
J
, Macleod
AM
, Muirhead
N
. Intermittent versus continuous renal replacement therapy for acute renal failure in adults
. Cochrane Database Syst Rev
. 2007
(3
):CD003773
. .7.
Ghahramani
N
, Shadrou
S
, Hollenbeak
C
. A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure
. Nephrology
. 2008
;13
(7
):570
–8
. .8.
Zhang
L
, Yang
J
, Eastwood
GM
, Zhu
G
, Tanaka
A
, Bellomo
R
. Extended daily dialysis versus continuous renal replacement therapy for acute kidney injury: a meta-analysis
. Am J Kidney Dis
. 2015
;66
(2
):322
–30
. .9.
Bagshaw
SM
, Wald
R
, Adhikari
NKJ
, Bellomo
R
, da Costa
BR
, Dreyfuss
D
, Timing of initiation of renal-replacement therapy in acute kidney injury
. N Engl J Med
. 2020
;383
(3
):240
–51
. .10.
Grooteman
MP
, van den Dorpel
MA
, Bots
ML
, Penne
EL
, van der Weerd
NC
, Mazairac
AH
, Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes
. J Am Soc Nephrol
. 2012
;23
(6
):1087
–96
. .11.
Kim
HW
, Yang
HN
, Kim
MG
, Choi
HM
, Jo
SK
, Cho
WY
, Microinflammation in hemodialysis patients is associated with increased CD14CD16(+) pro-inflammatory monocytes: possible modification by on-line hemodiafiltration
. Blood Purif
. 2011
;31
(4
):281
–8
. .12.
Peters
SA
, Bots
ML
, Canaud
B
, Davenport
A
, Grooteman
MP
, Kircelli
F
, Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials
. Nephrol Dial Transplant
. 2016
;31
(6
):978
–84
. .13.
Basile
C
, Davenport
A
, Blankestijn
PJ
. Why choose high volume online post-dilution hemodiafiltration?
J Nephrol
. 2017
;30
(2
):181
–6
. .14.
Maduell
F
, Moreso
F
, Pons
M
, Ramos
R
, Mora-Macià
J
, Carreras
J
, High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients
. J Am Soc Nephrol
. 2013
;24
(3
):487
–97
. .15.
Ronco
C
. Hemodiafiltration: technical and clinical issues
. Blood Purif
. 2015
;40
(Suppl 1
):2
–11
. .16.
Ok
E
, Asci
G
, Toz
H
, Ok
ES
, Kircelli
F
, Yilmaz
M
, Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF study
. Nephrol Dial Transplant
. 2013
;28
(1
):192
–202
. .17.
Wald
R
, Friedrich
JO
, Bagshaw
SM
, Burns
KE
, Garg
AX
, Hladunewich
MA
, Optimal mode of clearance in critically ill patients with acute kidney injury (OMAKI): a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project
. Crit Care
. 2012
;16
(5
):R205
. .18.
Wang
AY
, Bellomo
R
. Renal replacement therapy in the ICU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy?
Curr Opin Crit Care
. 2018
;24
(6
):437
–42
. .19.
Moher
D
, Liberati
A
, Tetzlaff
J
, Altman
DG
, Group
P
. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
. BMJ
. 2009
;339
:b2535
. .20.
Sterne
JAC
, Savović
J
, Page
MJ
, Elbers
RG
, Blencowe
NS
, Boutron
I
, RoB 2: a revised tool for assessing risk of bias in randomised trials
. BMJ
. 2019
;366
:l4898
. .21.
Abe
M
, Okada
K
, Suzuki
M
, Nagura
C
, Ishihara
Y
, Fujii
Y
, Comparison of sustained hemodiafiltration with continuous venovenous hemodiafiltration for the treatment of critically ill patients with acute kidney injury
. Artif Organs
. 2010
;34
(4
):331
–8
. .22.
Barrios-Araya
S
, Espinoza-Coya
ME
, Ñuñez-Gómez
K
, Sepúlveda-Palamara
R
, Molina-Muñoz
Y
. [Experience with inline intermittent hemodiafiltration as renal replacement therapy in critically ill patients]
. Rev Med Chil
. 2019
;147
(4
):409
–15
. .23.
Chancharoenthana
W
, Tiranathanagul
K
, Srisawat
N
, Susantitaphong
P
, Leelahavanichkul
A
, Praditpornsilpa
K
, Enhanced vascular endothelial growth factor and inflammatory cytokine removal with online hemodiafiltration over high-flux hemodialysis in sepsis-related acute kidney injury patients
. Ther Apher Dial
. 2013
;17
(5
):557
–63
. .24.
Klouche
K
, Amigues
L
, Serveaux-Delous
M
, Machado
S
, Delabre
JP
, Laydet
E
, Implementing on-line hemodiafiltration as a renal replacement therapy for ICU acute renal failure: a single-center report of feasibility, safety and hemodynamic tolerance over a seven-year period
. Blood Purif
. 2012
;34
(1
):10
–7
. .25.
Pettila
V
, Tiula
E
. Intermittent hemodiafiltration in acute renal failure in critically ill patients
. Clin Nephrol
. 2001
;56
(4
):324
–31
.26.
Skofic
N
, Arnol
M
, Buturovic-Ponikvar
J
, Ponikvar
R
. Intermittent high-volume predilution on-line haemofiltration versus standard intermittent haemodialysis in critically ill patients with acute kidney injury: a prospective randomized study
. Nephrol Dial Transplant
. 2012
;27
(12
):4348
–56
. .27.
Kutlay
S
, Kurultak
I
, Nergizoglu
G
, Erturk
S
, Karatan
O
. Optimal treatment in critically ill patients with acute kidney injury: Comparison of intermittant hemofiltration and hemodialysis in a randomized controlled trial
. Nephrol Dial Transplant
. 2013
;28
:i331
.28.
Nayak
S
, Prabhahar
A
, Bahuguna
P
, Gupta
KL
, Kohli
HS
, Ramachandran
R
, Sun-003 online hemodiafiltration (post-dilution) as compared to high flux hemodialysis does not improve outcomes in community acquired aki with sirs- a randomised controlled trial
. Kidney Int Rep
. 2020
;5
(3
):S205
–6
. .29.
Taratufolo
A
, Manzi
M
, Pedulla
F
, De Bernardini
F
, Carofei
O
, Alaimo
MR
, Haemodialysis in acute renal failure
. EDTNA ERCA J
. 1999
;25
(3
):43
–4
.30.
Ridgeon
EE
, Young
PJ
, Bellomo
R
, Mucchetti
M
, Lembo
R
, Landoni
G
. The fragility index in multicenter randomized controlled critical care trials
. Crit Care Med
. 2016
;44
(7
):1278
–84
. .31.
Centre of Research in Epidemiology and Statistics
. Fragility index of meta-analyses
. 2020 Oct
. Available from: http://clinicalepidemio.fr/fragility_ma/.32.
Rewa
OG
, Tolwani
A
, Mottes
T
, Juncos
LA
, Ronco
C
, Kashani
K
, Quality of care and safety measures of acute renal replacement therapy: workgroup statements from the 22nd acute disease quality initiative (ADQI) consensus conference
. J Crit Care
. 2019
;54
:52
–7
. .33.
Kidney Disease: Improving Global Outcomes (KDIGO)
. Clinical practice guidelines for acute kidney injury
. 2012
. Available from: 2020 Oct https://kdigo.org/guidelines/.34.
Tattersall
JE
, Ward
RA
, group
E
. Online haemodiafiltration: definition, dose quantification and safety revisited
. Nephrol Dial Transplant
. 2013
;28
(3
):542
–50
. .35.
Chapdelaine
I
, de Roij van Zuijdewijn
CL
, Mostovaya
IM
, Lévesque
R
, Davenport
A
, Blankestijn
PJ
, Optimization of the convection volume in online post-dilution haemodiafiltration: practical and technical issues
. Clin Kidney J
. 2015
;8
(2
):191
–8
. .36.
Maduell
F
. Is there an “optimal dose” of hemodiafiltration?
Blood Purif
. 2015
;40
(Suppl 1
):17
–23
. .37.
Kron
J
, Kron
S
, Wenkel
R
, Schuhmacher
HU
, Thieme
U
, Leimbach
T
, Extended daily on-line high-volume haemodiafiltration in septic multiple organ failure: a well-tolerated and feasible procedure
. Nephrol Dial Transplant
. 2012
;27
(1
):146
–52
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
